AI-extracted from the 10-Q filed 2026-10-13 — Q3 FY2026 (quarter ended August 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Nurix reported $673.1M total revenue in Q3 FY2026, primarily driven by $653.2M license revenue from the Roche bexobrutideg collaboration upfront payment.
Biggest Revenue Drivers
License revenue$653.2MN/A (no prior year comparable)
Development and Commercialization License for bexobrutideg granted to Roche under the June 2026 collaboration agreement, which became effective July 2026.
Biggest Revenue Drivers
License revenue$653.2MN/A (no prior year comparable)
Development and Commercialization License for bexobrutideg granted to Roche under the June 2026 collaboration agreement, which became effective July 2026.
Largest Expense Items
Research and development$79.3M-8% YoY
Cost-sharing offset related to Roche Collaboration Agreement and decrease in contract manufacturing due to timing.
Watch Items from the Filing
Lead program dependency: Bexobrutideg (NX-5948) under Roche collaboration is the company's lead asset; discontinued zelebrudomide (NX-2127) development in August 2026 as part of portfolio prioritization.
Cash position: $1.1B in cash, cash equivalents and marketable securities as of August 31, 2026; company expects existing resources sufficient for at least 12 months of operations.
Collaboration termination risks: Sanofi may terminate its agreement upon a change of control; each of Gilead, Sanofi, Pfizer and Roche can terminate for convenience or material breach.
Clinical trial execution: Phase 3 DAYBreak CLL-306 trial for bexobrutideg enrolled first patient in August 2026; Phase 1 NX-1607 trial ongoing; execution delays could impact milestones and royalties.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Dansey Roger DDirectorGrant or award · May 15, 2026
Kapur AnilDirectorGrant or award · May 15, 2026
Lacey David L.DirectorGrant or award · May 15, 2026
Reinsdorf Judith ADirectorGrant or award · May 15, 2026
Saltzman Edward CDirectorGrant or award · May 15, 2026
About Nurix Therapeutics, Inc. (NRIX): stock profile, AI score and financials
Nurix Therapeutics, Inc. (NRIX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRIX at 6.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,910 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (2.2) and profitability (2.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Nurix Therapeutics, Inc. reports quarterly revenue of $673.1M, net income of $549.8M, an operating margin of 83.1%. Top institutional holders of NRIX by reported 13-F value include BlackRock, Vestal Point Capital, Deep Track Capital, based on the most recent SEC filings. NRIX trades on the Nasdaq exchange and files with the SEC under CIK 1549595. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nurix Therapeutics, Inc. directly from SEC EDGAR.